AR104271A1 - Vacuna contra las paperas en base al virus jeryl lynn 2 recombinante - Google Patents

Vacuna contra las paperas en base al virus jeryl lynn 2 recombinante

Info

Publication number
AR104271A1
AR104271A1 ARP160100823A ARP160100823A AR104271A1 AR 104271 A1 AR104271 A1 AR 104271A1 AR P160100823 A ARP160100823 A AR P160100823A AR P160100823 A ARP160100823 A AR P160100823A AR 104271 A1 AR104271 A1 AR 104271A1
Authority
AR
Argentina
Prior art keywords
recombinant
paperas
vaccine against
jeryl lynn
virus
Prior art date
Application number
ARP160100823A
Other languages
English (en)
Inventor
Gupta Gaurav
Giannino Viviana
Glueck Reinhard
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of AR104271A1 publication Critical patent/AR104271A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18721—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18741—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18751—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18761—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente proporciona una vacuna contra las paperas compuesta de rMuVJL² (paperas en base al virus Jeryl Lynn 2 recombinante). Además, en la presente se describe el método para desarrollar dicha composición inmunogénica. De acuerdo con la presente, la vacuna es segura, rentable, altamente efectiva y estable y consistente en términos de productividad.
ARP160100823A 2015-03-27 2016-03-29 Vacuna contra las paperas en base al virus jeryl lynn 2 recombinante AR104271A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1055MU2015 2015-03-27

Publications (1)

Publication Number Publication Date
AR104271A1 true AR104271A1 (es) 2017-07-12

Family

ID=55948921

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160100823A AR104271A1 (es) 2015-03-27 2016-03-29 Vacuna contra las paperas en base al virus jeryl lynn 2 recombinante

Country Status (21)

Country Link
EP (1) EP3274447B1 (es)
JP (2) JP2018510642A (es)
KR (1) KR101970428B1 (es)
CN (1) CN107667175A (es)
AR (1) AR104271A1 (es)
AU (1) AU2016242460B2 (es)
BR (1) BR112017020643A2 (es)
CA (1) CA2980847C (es)
DK (1) DK3274447T3 (es)
ES (1) ES2764677T3 (es)
HR (1) HRP20200018T1 (es)
HU (1) HUE047571T2 (es)
IL (1) IL254698A0 (es)
LT (1) LT3274447T (es)
MX (1) MX2017012389A (es)
PL (1) PL3274447T3 (es)
PT (1) PT3274447T (es)
RS (1) RS59774B1 (es)
SG (1) SG11201707904XA (es)
SI (1) SI3274447T1 (es)
WO (1) WO2016157208A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107233576B (zh) * 2017-08-08 2020-02-07 江苏省农业科学院 耐热保护剂、猪瘟可室温保存活疫苗及其制备方法和应用
CN111218473A (zh) * 2018-11-23 2020-06-02 成都生物制品研究所有限责任公司 一种拯救腮腺炎病毒的系统和方法
CN109593784A (zh) * 2019-01-14 2019-04-09 浙江大学 一种用于拯救腮腺炎病毒的系统及拯救方法
CN109628414B (zh) * 2019-01-14 2021-03-30 浙江大学 一种mRNA甲基转移酶缺陷型腮腺炎病毒及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122007000003I2 (de) * 1993-11-19 2011-01-13 Glaxosmithkline Biolog Sa Gegen mumps impfstoff, der ein virus des jeryl-lynn stammes enthält
CA2333313C (en) * 1998-06-03 2011-11-08 American Cyanamid Company Novel methods for rescue of rna viruses
CN1384877B (zh) * 1999-08-02 2010-10-27 惠氏 从cDNA拯救腮腺炎病毒
KR100999316B1 (ko) * 2003-06-09 2010-12-10 와이어쓰 엘엘씨 ｃＤＮＡ로부터의 비분절 네가티브 쇄 ＲＮＡ 바이러스의회수를 위한 개선된 방법
EP1951865A4 (en) * 2005-11-21 2010-06-23 Sanofi Pasteur Ltd STABILIZING FORMULATIONS FOR RECOMBINANT VIRUSES
CN104862335A (zh) * 2009-07-31 2015-08-26 诺华股份有限公司 反向遗传系统

Also Published As

Publication number Publication date
HUE047571T2 (hu) 2020-04-28
EP3274447B1 (en) 2019-10-16
PL3274447T3 (pl) 2021-07-19
CA2980847C (en) 2020-03-24
KR101970428B1 (ko) 2019-04-18
AU2016242460A1 (en) 2017-10-19
SG11201707904XA (en) 2017-10-30
WO2016157208A1 (en) 2016-10-06
JP2020074792A (ja) 2020-05-21
SI3274447T1 (sl) 2020-03-31
EP3274447A1 (en) 2018-01-31
LT3274447T (lt) 2020-02-10
RS59774B1 (sr) 2020-02-28
CA2980847A1 (en) 2016-10-06
DK3274447T3 (da) 2020-01-27
PT3274447T (pt) 2020-01-21
MX2017012389A (es) 2018-09-19
JP2018510642A (ja) 2018-04-19
ES2764677T3 (es) 2020-06-04
HRP20200018T1 (hr) 2020-03-20
BR112017020643A2 (pt) 2018-07-17
CN107667175A (zh) 2018-02-06
WO2016157208A9 (en) 2017-03-16
IL254698A0 (en) 2017-11-30
AU2016242460B2 (en) 2019-04-18
KR20170131659A (ko) 2017-11-29

Similar Documents

Publication Publication Date Title
BR112018013387A2 (pt) vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit
CL2018000320A1 (es) Coadyuvantes basados en aceite (divisional de solicitud 201600650)
EP4233898A3 (en) Influenza mrna vaccines
CL2019003264A1 (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas. (divisional solicitud 201703151)
PH12020500080A1 (en) Senecavirus a immunogenic compositions and methods thereof
AR105434A1 (es) Proceso para preparar pridopidina
MX2020004543A (es) Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan.
CL2016002794A1 (es) Vacuna de péptido que comprende un péptido ras mutante y un agente quimioterapéutico
AR102547A1 (es) Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
AR104271A1 (es) Vacuna contra las paperas en base al virus jeryl lynn 2 recombinante
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
CO2021010786A2 (es) Toxinas apxia, apxiia y apxiiia inactivadas
BR112018070497A2 (pt) métodos e formulações farmacêuticas para tratamento de condições oculares
PH12017500450A1 (en) Flavivirus virus like particle
MX2020004633A (es) Metodo para inactivar el virus de zika y metodos relacionados.
BR112019001115A2 (pt) proteínas de biofusão como vacinas anti-malária
BR112016022787A2 (pt) método para induzir uma resposta imune em um indivíduo humano, composição imunogênica, e, uso de uma segunda composição imunogênica
MX2018014955A (es) Vacunas atenuadas vivas del virus de la influenza equina.
CR20160369A (es) Composiciones para uso en el tratamiento de afecciones alérgicas
EA201991319A1 (ru) Вакцины аттенуированного свиного гриппа и способы их изготовления и применения
AR106501A1 (es) Adyuvante y composición de vacuna que lo contiene
AR106221A1 (es) Una composición de toxicidad baja
EA202090236A1 (ru) Иммуногенные композиции senecavirus a и способы с ними
EA201992167A1 (ru) Вакцина

Legal Events

Date Code Title Description
FB Suspension of granting procedure